Labcorp will offer Roche's FDA-cleared Elecsys pTau181 blood test to detect early signs of Alzheimer's disease in patients 55 and older. The minimally invasive test, developed with Eli Lilly, measures the pTau 181 protein, a biomarker for Alzheimer's.

Guardant Health and Zephyr AI are collaborating to advance cancer research by combining artificial intelligence and machine learning technologies with multimodal molecular data. The partnership aims to speed up the development of cancer biomarkers.

Abselion has introduced the Protein G Total Antibody Quantification Kit for its Amperia benchtop platform, expanding its antibody quantification capabilities. The new kit allows researchers to measure a broader range of antibody isotypes and species using a sensitive electrochemical readout.

Eli Lilly is acquiring Adverum Therapeutics in a deal valued at $74 million upfront, with potential for up to $260 million, to enhance its gene therapy portfolio. Adverum's lead candidate, ixoberogene soroparvovec, is a gene therapy for wet age-related macular degeneration that has reached Phase III trials.

Noul has supplied its AI-powered malaria diagnostic solution, miLab MAL, to Germany's top hospital. The platform automates blood and cancer diagnostics, reducing sample preparation and reading time, which can lower costs.

Genie Fertility has received $1.2 million in funding to develop an AI-powered test for uterine health using menstrual blood. The test aims to improve fertility outcomes, particularly for women undergoing IVF and the funding will support clinical studies and expand research into additional biomarkers and diagnostic tests.

Novartis will pay about $12 billion to acquire Avidity Biosciences, a biotechnology company specializing in RNA therapeutics. The acquisition will add three late-stage neuromuscular programs to Novartis's neuroscience pipeline, including treatments for Duchenne muscular dystrophy, myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy.

Sarah Yim, director of the Office of Therapeutic Biologics and Biosimilars at the FDA, has highlighted a potential biosimilar void as many biologic drugs are set to lose patent protection between 2025 and 2034. According to a report from IQVIA, biosimilars are in development for just 12 of 118 biologics that will lose patent protection, leaving 106 products with little or no competition. Yim said the FDA is working to streamline the review process for biosimilars to make development more economically feasible and more closely align with the process for generic drugs.

The NIH has awarded a $3 million grant to CND Life Sciences to study the Syn-One Test, which uses a skin punch biopsy to detect phosphorylated alpha-synuclein, a biomarker associated with Parkinson's disease. The study will examine whether the presence of the protein in people who have essential tremor can be used to predict risk of developing Parkinson's disease.

The University of Alabama at Birmingham has inaugurated the Altec/Styslinger Genomic Medicine and Data Sciences Building, a state-of-the-art facility aimed at advancing biomedical research and innovation. Funded by a $50 million investment from the state of Alabama, the building is designed to foster the development of new drugs and medical startups. It houses over 90 researchers focused on tackling diseases like cancer and diabetes using data science and genomic engineering.

Call for Proposals for ADLM 2026
Deadline: Thursday, November 6, 2025
Submit your proposal!

Share your expertise, research, and innovations with a global audience at the leading event in clinical diagnostics and laboratory science. Whether your focus is cutting-edge technology, clinical applications, or emerging science, we invite you to submit a session that sparks conversation and advances the field.

November 7, 2025 | Cleveland, OH
Register today

Join us for the 2025 ADLM Point-of-Care Testing Conference--a focused one-day event designed to help you strengthen your POCT program with proven tools, strategies, and real-world insights. Learn how to build more effective training and competency programs, enhance quality management, and successfully manage interfaced instrument projects.